Philip Nickson Biography and Net Worth

As Chief Business and Legal Officer, Phil leads Monte Rosa’s business development and legal departments to support the company’s evolving strategic goals as we leverage our prolific QuEEN discovery engine to generate novel potential MGD therapeutics and advance our industry-leading pipeline of MGDs towards patients. Phil joined Monte Rosa in 2021 to support the company’s IPO. Prior to joining Monte Rosa, Phil spent 10+ years with Momenta Pharmaceuticals until the company’s acquisition by Johnson and Johnson in 2020, and then spent around 1 year with JnJ supporting integration of Momenta into JnJ. During his time at Momenta, Phil was pivotal in the discovery, development, and ultimately sale, of the company’s anti-FcRn antibody, nipocalimab, for use in multiple immunological indications. Phil also built innovative business and legal solutions to support the company’s diverse pipeline of novel large and small molecule therapeutics, biosimilars, and generics, and he built and supported multiple strategic partnerships, including with CSL, Mylan, Sandoz. Phil spent his early legal career as a patent attorney with Fish and Richardson in Boston where he focused his practice on supporting small to mid-size biotech clients. Prior to practicing law, Phil completed a post-doctoral research program at the Boston Biomedical Research Institute researching cardiomyocyte cell death. Phil holds a J.D. from Suffolk University and a Ph.D. from University of Manchester. Phil currently lives with his family in Lincoln, Massachusetts.